Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer

Clinics

Volumn 66, Issue 7, 2011, Pages 1143-1147

  dos Reis, Sabrina Thalita ^a   Pontes Júnior, José ^a   Antunes, Alberto Azoubel ^a   de Sousa Canavez, Juliana Moreira ^b   Abe, Daniel Kanda ^a   da Cruz, José Arnaldo Shiomi ^a   Dall'Oglio, Marcos Francisco ^a   Crippa, Alexandre ^a   Passerotti, Carlo Camargo ^a   Ribeiro Filho, Leopoldo A ^a   Viana, Nayara Izabel ^a   Sroug, Miguel ^a   Leite, Kátia Ramos Moreira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Genoa Biotechnology SA   (Brazil)

Author keywords

Molecular markers; Prognosis; Prostate cancer; TGF b

Indexed keywords

CARCINOGEN; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CANCER GRADING; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; CARCINOGENS; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 80052182957     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000700004     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249. Epub 2009 May 27 doi: 10.3322/caac.20006.
2. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-51.
3. Derynck R, Jarret JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-β complementary DNA sequences and expression in normal and transformed cells. Nature. 1985;316:701-5 doi: 10.1038/316701a0.
4. Madison L, Webb NR, Rose TM, Marquardt H, Ikeda T, Twardzik D, et al. Transforming growth factor-βeta 2: cDNA cloning and sequence analysis. DNA. 1988;7:1-8 doi: 10.1089/dna.1988.7.1.
5. Sutkowski DM, Fong C-J, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, et al. Interaction of epidermal growth factor and transforming growth factor-β1 in human prostatic epithelial cells in culture. Prostate. 1992;21:133-43 doi: 10.1002/pros.2990210206.
6. Wilding G. Response of prostate cancer cells to peptide growth factor: transforming growth factor-β. Cancer Surv. 1991;11:147-63 doi: 10.3167/001115799782483762.
7. Alexandrow MG, Moses HL. Transforming growth factor b and cell cycle regulation. Cancer Res. 1995;55:1452-7.
8. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, et al. Transforming Growth Factor-β in Benign and Malignant Prostate. The Prostate. 1999; 39:285-90 doi: 10.1002/(SICI)1097-0045(19990601) 39:4,285::AID-PROS9.3.0.CO;2-7.
9. Yang EY, Moses HL. Transforming growth factor b1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990;111:731-41 doi: 10.1083/jcb.111.2.731.
10. Soulitzis N, Karyotis I, Delakas D, Spandidos D. Expression analysis of peptides growth factors VEGF, FGF2, TGFb1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int. Journal of Oncology. 2006;29:305-14.
11. Sutkowski DM, Fong C-J, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, et al. Interaction of epidermal growth factor and transforming growth factor-β1 in human prostatic epithelial cells in culture. Prostate. 1992;21:133-43 doi: 10.1002/pros.2990210206.
12. Wilding G. Response of prostate cancer cells to peptide growth factor: transforming growth factor-β. Cancer Surv. 1991;11:147-63 doi: 10.3167/001115799782483762.
13. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology. 1990;127:2963-8 doi: 10.1210/endo-127-6-2963.
14. Franzén P, Ichijo H, Miyazono K. Different signals mediate transforming growth factor-βeta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res. 1993;207:1-7 doi:10.1006/excr.1993.1156.
15. Edwards DR, Leco KJ, Beaudry PP, Atadja PW, Veillette C, Riabowol KT. Differential effects of transforming growth factor-βeta1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp Gerontol. 1996;31:207-23 doi: 10.1016/0531-5565(95)02010-1.
16. Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, et al. Thrombospondin and transforming growth factor-βeta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer. 1995;76:998-1005 doi: 10.1002/1097-0142(19950915)76:6,998::AIDCNCR2820760613.3.0.CO;2-0.
17. Matrisian LM. Matrix metalloproteinase gene expression. Ann NY Acad Sci. 1994;732:42-50 doi: 10.1111/j.1749-6632.1994.tb24723.x.
18. Shariat SF, Menesses-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Tissue expression of transforming growth factor-eta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004;63:1191-7 doi: 10.1016/j.urology.2003.12.015.
19. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM et al. Association of pre and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992-9 doi: 10.1158/1078-0432.CCR-0768-03.
20. Faria PC, Saba K, Neves AF, Cordeiro ER, Marangoni K, Freitas DG, Goulart LR. Transforming Growth Factor-βeta1 gene polymorphisms and expression in the blood of Prostate Cancer patients. Cancer investigation. 2007;725:726-32.
21. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature. 1994;370:341-7 doi: 10.1038/370341a0.
22. Barrack ER. TGF-β on prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate. 1997;31:61-70 doi: 10.1002/(SICI)1097-0045(19970401)31:1,61::AID-PROS10.3.0.CO;2-M.
23. Bello-DeOcampo D, Tindall DJ. TGF-βetal/Smad signaling in prostate cancer. Curr Drug Targets. 2003;4:197-207 doi: 10.2174/1389450033491118.
24. Prindull G, Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood. 2004;103: 2892-99 doi: 10.1182/blood-2003-08-2807.
25. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol. 1998;16:137-61 doi: 10.1146/annurev.immunol.16.1.137.